3 results
Approved WMOPending
The Primary objective is to assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg/ valsartan 320 mg in patients with essential hypertension (msDBP > 90 mmHg and < 110 mmHg.
Approved WMOWill not start
To compare the antiproteinuric effects of sacubitril/valsartan (ARNI) and valsartan (ARB).
Approved WMORecruiting
The purpose of this scientific study is to verify whether immunotherapy (L19-IL2) after a standard treatment such as radiotherapy, fights the metastatic disease more efficiently than the current standard treatment alone.